 |
|
|
|
|
New Mexico Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New MexicoLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Affymax, Inc.
| | | | | Phone: | (650) 812-8700 | | Year Established: | 2001 | | Ticker: | AFFY | | Exchange: | OTCQB | | Main Contact: | Rich Brenner, CEO | | | | Company Description | | Affymax is a biopharmaceutical company creating novel approaches for improving patient care for serious and life-threatening conditions in kidney disease. Hematide™, our first product candidate to enter the clinic, is a novel peptide-based drug designed to stimulate the production of red blood cells. It is currently in Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is an erythropoiesis-stimulating agent (ESA) that, if proven safe and effective in clinical trials, may improve the management of anemia and offer patients and physicians an alternative therapy to recombinant erythropoietin products currently on the market. | |
|
|
|
|
|
|
|
